Drug intelligence / Profile preview

WPC01

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

WPC01 is a small molecule inhibitor targeting the mitogen-activated protein kinase (MAPK) signaling pathway, currently in the drug optimization stage of development by Westlake Pharmaceuticals. The MAPK pathway is a central regulator of cellular processes including growth, proliferation, and survival; its aberrant activation is a hallmark of many human cancers. By inhibiting components of this pathway, WPC01 aims to suppress tumor progression. It is part of a series of MAPK-targeted assets (WPC01-WPC05) being explored by the sponsor for oncological indications.

Targets

MEK

Beyond the preview

Go deeper on WPC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPC01.

Explore the full profile